Statement: In anemic elderly patients (aged ≥ 75 years) with non-dialysis CKD, we suggest maintaining hemoglobin levels within the target range of 11–13 g/dL using erythropoietin-stimulating agents (ESAs) and/or iron supplementation. This evidence concerns the gene EPO and chronic kidney disease.